Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Cellectar to Participate

in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PARK, N.J., September 15, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical

company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and

CEO, will present a company overview at the following upcoming conference:

Oppenheimer Fall Healthcare

Life Sciences & MedTech Summit

replay of the presentation will be available on the Events Page of the company's website (www.cellectar.com).

About Cellectar Biosciences, Inc.

Cellectar Biosciences

is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently

and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug

Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better

safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development

of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development

The company's product

pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary

preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is currently enrolling in a global, pivotal Phase

2 Part B (CLOVER-WaM) expansion study in WM patients who have received at least two prior lines of therapy, including Bruton tyrosine

kinase inhibitor failed or suboptimal response patients. The WM study will enroll up to 50 patients to evaluate the efficacy and safety

of iopofosine for marketing approval.

more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and

following us on the company's social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer

This news release contains

forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe,"

"anticipate," "intend," "could," "estimate," "continue," "plans," or their

negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties

that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current

beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery

and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties

related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine,

the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development

thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability

to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical

collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product

pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic

reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020. These forward-looking

statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.